Prevention and management of TURP-related hemorrhage

Nature Reviews Urology

Volumn 8, Issue 9, 2011, Pages 504-514

  Kavanagh, Liam E ^a   Jack, Gregory S ^a   Lawrentschuk, Nathan ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADRENALIN; AMINOCAPROIC ACID; ANTITHROMBOCYTIC AGENT; APROTININ; CLOPIDOGREL; DABIGATRAN; DIPYRIDAMOLE; DUTASTERIDE; FINASTERIDE; HEPARIN; IBUPROFEN; INDOMETACIN; LOW MOLECULAR WEIGHT HEPARIN; NAPROXEN; PRASUGREL; RIVAROXABAN; STEROID 5ALPHA REDUCTASE INHIBITOR; THIENOPYRIDINE DERIVATIVE; THROMBOXANE; TIROFIBAN; TRANEXAMIC ACID; WARFARIN;

ACUTE CORONARY SYNDROME; BLEEDING; CARDIOVASCULAR RISK; DEEP VEIN THROMBOSIS; HEART ATRIUM FIBRILLATION; HEMATURIA; HEMOSTASIS; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; LASER; LUNG EMBOLISM; PERIOPERATIVE COMPLICATION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; REVIEW; RISK ASSESSMENT; STROKE; SURGICAL TECHNIQUE; THROMBOGENESIS; TRANSURETHRAL RESECTION; UNSTABLE ANGINA PECTORIS;

ANIMALS; DISEASE MANAGEMENT; HUMANS; LASER THERAPY; MALE; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE HEMORRHAGE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; TRANSURETHRAL RESECTION OF PROSTATE;

EID: 80052712152     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2011.106     Document Type: Review

References (100)

1. Mebust, W. K., Holtgrewe, H. L., Cockett, A. T. & Peters, P. C. Transurethral prostatectomy: immediate and postoperative complications. Cooperative study of 13 participating institutions evaluating 3,885 patients. 1989. J. Urol. 167, 999-1003 (2002).
2. Wendt-Nordahl, G. et al. New bipolar resection device for transurethral resection of the prostate: first ex-vivo and in-vivo evaluation. J. Endourol. 19, 1203-1209 (2005). (Pubitemid 43082916)
3. Wendt-Nordahl, G. et al. Improvement in mortality and morbidity in transurethral resection of the prostate over 17 years in a single center. J. Endourol. 21, 1081-1087 (2007). (Pubitemid 47608933)
4. Uchida, T. et al. Factors influencing morbidity in patients undergoing transurethral resection of the prostate. Urology 53, 98-105 (1999). (Pubitemid 29016622)
5. Reich, O. et al. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J. Urol. 180, 246-249 (2008).
6. Descazeaud, A. et al. Impact of oral anticoagulation on morbidity of transurethral resection of the prostate World J. Urol. 29, 211-216 (2010).
7. Ahyai, S. A. et al. Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur. Urol. 58, 384-397 (2010).
8. Go, A. S. et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285, 2370-2375 (2001). (Pubitemid 32424106)
9. Lebdai, S. et al. Management of patients under anticoagulants for transurethral resection of the prostate: a multicentric study by the CTMH-AFU [French]. Prog. Urol. 19, 553-557 (2009).
10. Lewis, H. D. Jr et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N. Engl. J. Med. 309, 396-403 (1983). (Pubitemid 13033964)
11. Hersh, E. V., Moore, P. A. & Ross, G. L. Over-the-counter analgesics and antipyretics: a critical assessment. Clin. Ther. 22, 500-548 (2000). (Pubitemid 30434308)
12. Petty, G. W. et al. Ischemic stroke subtypes: a population-based study of functional outcome, survival, and recurrence. Stroke 31, 1062-1068 (2000). (Pubitemid 30253526)
13. Mant, J. et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 370, 493-503 (2007). (Pubitemid 47212371)
14. Heit, J. A. Perioperative management of the chronically anticoagulated patient. J. Thromb. Thrombolysis 12, 81-87 (2001). (Pubitemid 33103846)
15. Salem, D. N., O'Gara, P. T., Madias, C. & Pauker, S. G. Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133, 593S-629S (2008). (Pubitemid 351892973)
16. Majerus, P. W. & Tollegsen, T. M. in Goodman & Gilman's The Pharmacological Basis of Therapeutics 11th edn (eds Brunton, L. L. Lazo, J. S. & Parker, K. L.) 1467-1488 (The McGraw-Hill Companies, New York, 2006).
17. Parr, N. J., Loh, C. S. & Desmond, A. D. Transurethral resection of the prostate and bladder tumour without withdrawal of warfarin therapy. Br. J. Urol. 64, 623-625 (1989). (Pubitemid 20040265)
18. Katholi, R. E., Nolan, S. P. & McGuire, L. B. Living with prosthetic heart valves. Subsequent noncardiac operations and the risk of thromboembolism or hemorrhage. Am. Heart J. 92, 162-167 (1976).
19. Mulcahy, J. J., Bradenburg, R. O., Pluth, J. R. & Greene, L. F. Transurethral prostatic resection in patients with prosthetic cardiac valves. J. Urol. 113, 642-643 (1975).
20. Wysokinski, W. E. et al. Periprocedural anticoagulation management of patients with nonvalvular atrial fibrillation. Mayo Clin. Proc. 83, 639-645 (2008). (Pubitemid 351810563)
21. Douketis, J. D. et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133, 299S-339S (2008). (Pubitemid 351894915)
22. Ansell, J. et al. Managing oral anticoagulant therapy. Chest 119, 22S-38S (2001). (Pubitemid 32154193)
23. Dunn, A. Perioperative management of oral anticoagulation: when and how to bridge. J. Thromb. Thrombolysis 21, 85-89 (2006). (Pubitemid 43231134)
24. Wilson, R. G., Smith, D., Paton, G., Gollock, J. M. & Bremner, D. N. Prophylactic subcutaneous heparin does not increase operative blood loss in transurethral resection of the prostate. Br. J. Urol. 62, 246-248 (1988).
25. Wittkowski, A. K. in Applied Therapeutics: The Clinical Use Of Drugs 6th edn (eds Young, L. Y. & Koda-Kimble, M. A.) 12.1-12.5 (Applied Therapeutics, Inc., Vancouver, 1995).
26. Dotan, Z. A. et al. The efficacy and safety of perioperative low molecular weight heparin substitution in patients on chronic oral anticoagulant therapy undergoing transurethral prostatectomy for bladder outlet obstruction. J. Urol. 168, 610-613 (2002).
27. Verma, A. K. New agents for orthopaedic thromboprophylaxis: caution essential, but time will tell. ANZ J. Surg. 79, 773-774 (2009).
28. Connolly, S. J. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361, 1139-1151 (2010).
29. Eriksson, B. I. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N. Engl. J. Med. 358, 2765-2775 (2008). (Pubitemid 351930851)
30. Levy, J. H., Key, N. S. & Azran, M. S. Novel oral anticoagulants: implications in the perioperative setting. Anesthesiology 113, 726-745 (2010).
31. Patrono, C., Coller, B., FitzGerald, G. A., Hirsh, J. & Roth, G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126, 234S-264S (2004). (Pubitemid 39297956)
32. Rang, H. P., Dale, M. M., Ritter, J. M. & Flower, R. J. (eds) Rang and Dale's Pharmacology 6th edn (Elsevier, Philadelphia, 2007).
33. [No authors listed] Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 2, 349-360 (1988).
34. Aguilar, M. & Hart, R. Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst. Rev. Issue 4. Art. No.: CD001925. doi:10.1002/14651858.CD001925.pub2 (2005).
35. Sonksen, J. R., Kong, K. L. & Holder, R. Magnitude and time course of impaired primary haemostasis after stopping chronic low and medium dose aspirin in healthy volunteers. Br. J. Anaesth. 82, 360-365 (1999). (Pubitemid 29112536)
36. Enver, M. K., Hoh, I. & Chinegwundoh, F. I. The management of aspirin in transurethral prostatectomy: current practice in the UK. Ann. R. Coll. Surg. Engl. 88, 280-283 (2006).
37. Wasson, J. H. et al. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. N. Engl. J. Med. 332, 75-79 (1995).
38. Doll, H. A. et al. Mortality, morbidity and complications following transurethral resection of the prostate for benign prostatic hypertrophy. J. Urol. 147, 1566-1573 (1992).
39. Gyomber, D., Lawrentschuk, N., Ranson, D. L. & Bolton, D. M. An analysis of deaths related to urological surgery, reviewed by the State Coroner: a case for cardiac vigilance before transurethral prostatectomy. BJU Int. 97, 758-761 (2006). (Pubitemid 43383509)
40. Ala-Opas, M. Y. & Grönlund, S. S. Blood loss in long-term aspirin users undergoing transurethral prostatectomy. Scand. J. Urol. Nephrol. 30, 203-206 (1996). (Pubitemid 26228182)
41. Nielsen, J. D. et al. The effect of low-dose acetylsalicylic acid on bleeding after transurethral prostatectomy-a prospective, randomized, double-blind, placebo-controlled study. Scand. J. Urol. Nephrol. 34, 194-198 (2000). (Pubitemid 32055269)
42. Ehrlich, Y. et al. Early initiation of aspirin after prostate and transurethral bladder surgeries is not associated with increased incidence of postoperative bleeding: a prospective, randomized trial. J. Urol. 178, 524-528 (2007). (Pubitemid 47030512)
43. Donat, R., McNeill, A. & Brame, K. Anti-platelet and non-steroidal anti-inflammatory drugs in transurethral surgery of the prostate and bleeding complications [abstract]. BJU Int. 77 (Suppl. 1), 31 (1996).
44. Burger, W., Chemnitius, J. M., Kneissl, G. D. & Rücker, G. Low-dose aspirin for secondary cardiovascular prevention-cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation-review and meta-analysis. J. Intern. Med. 257, 399-414 (2005). (Pubitemid 40604544)
45. Hall, R. & Mazer, C. D. Antiplatelet drugs: a review of their pharmacology and management in the perioperative period. Anesth. Analg. 112, 292-318 (2011).
46. Weber, A. A. et al. Recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers. Br. J. Clin. Pharmacol. 52, 333-336 (2001).
47. Wiviott, S. D. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357, 2001-2015 (2007). (Pubitemid 350106708)
48. Schouten, O. et al. Noncardiac surgery after coronary stenting: early surgery and interruption of antiplatelet therapy are associated with an increase in major adverse cardiac events. J. Am. Coll. Cardiol. 49, 122-124 (2007). (Pubitemid 46026891)
49. Montalescot, G. et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 373, 723-731 (2009).
50. Eberli, D. et al. Urological surgery and antiplatelet drugs after cardiac and cerebrovascular accidents. J. Urol. 183, 2128-2136 (2010).
51. Halkes, P. H. et al. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 367, 1665-1673 (2006).
52. de Gaetano, G. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 357, 89-95 (2001).
53. Petry, J. J. Surgically significant nutritional supplements. Plast. Reconstr. Surg. 97, 233-240 (1996).
54. McConnell, J. D. et al. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J. Clin. Endocrinol. Metab. 74, 505-508 (1992).
55. Guess, H. A., Gormley, G. J., Stoner, E. & Oesterling, J. E. The effect of finasteride on prostate specific antigen: review of available data. J. Urol. 155, 3-9 (1996). (Pubitemid 126426420)
56. Donohue, J. F., Hayne, D., Karnik, U., Thomas, D. R. & Foster, M. C. Randomized, placebo-controlled trial showing that finasteride reduces prostatic vascularity rapidly within 2 weeks. BJU Int. 96, 1319-1322 (2005). (Pubitemid 41743932)
57. Hochberg, D. A. et al. Decreased suburethral prostatic microvessel density in finasteride treated prostates: a possible mechanism for reduced bleeding in benign prostatic hyperplasia. J. Urol. 167, 1731-1733 (2002). (Pubitemid 34240714)
58. Foley, S. J. & Bailey, D. M. Microvessel density in prostatic hyperplasia. BJU Int. 85, 70-73 (2000). (Pubitemid 30072452)
59. Kashif, K. M. Haematuria associated with BPH-Natural history and a new treatment option. Prostate Cancer Prostatic Dis. 1, 154-156 (1998). (Pubitemid 128545859)
60. Puchner, P. J. & Miller, M. I. The effects of finasteride on hematuria associated with benign prostatic hyperplasia: a preliminary report. J. Urol. 154, 1779-1782 (1995).
61. Sieber, P. R. et al. The treatment of gross hematuria secondary to prostatic bleeding with finasteride. J. Urol. 159, 1232-1233 (1998). (Pubitemid 28172803)
62. Kearney, M. C., Bingham, J. B., Bergland, R., Meade-D'Alisera, P. & Puchner, P. J. Clinical predictors in the use of finasteride for control of gross hematuria due to benign prostatic hyperplasia. J. Urol. 167, 2489-2491 (2002). (Pubitemid 34533153)
63. Foley, S. J. et al. A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride. J. Urol. 163, 496-498 (2000). (Pubitemid 30060503)
64. Donohue, J. F. & Barber, N. J. How do we investigate haematuria and what role has finasteride? BJU Int. 93, 3-4 (2004). (Pubitemid 38112951)
65. Ozdal, O. L. et al. Effect of short-term finasteride therapy on peroperative bleeding in patients who were candidates for transurethral resection of the prostate (TUR-P): a randomized controlled study. Prostate Cancer Prostatic Dis. 8, 215-218 (2005). (Pubitemid 43118056)
66. Donohue, J. F. et al. Transurethral prostate resection and bleeding: a randomized, placebo controlled trial of role of finasteride for decreasing operative blood loss. J. Urol. 168, 2024-2026 (2002).
67. Sandfeldt, L., Bailey, D. M. & Hahn, R. G. Blood loss during transurethral resection of the prostate after 3 months of treatment with finasteride. Urology 58, 972-976 (2001). (Pubitemid 34017283)
68. Hagerty, J. A., Ginsberg, P. C., Harmon, J. D. & Harkaway, R. C. Pretreatment with finasteride decreases perioperative bleeding associated with transurethral resection of the prostate. Urology 55, 684-689 (2000).
69. Hahn, R. G. et al. Blood loss and postoperative complications associated with transurethral resection of the prostate after pretreatment with dutasteride. BJU Int. 99, 587-594 (2007). (Pubitemid 46238833)
70. Tuncel, A. et al. Effects of short-term dutasteride and Serenoa repens on perioperative bleeding and microvessel density in patients undergoing transurethral resection of the prostate. Scand. J. Urol. Nephrol. 43, 377-382 (2009).
71. McVary, K. T. et al. Update on AUA Guideline on the Management of Benign Prostatic Hyperplasia. J. Urol. 185, 1793-1803 (2011).
72. Rannikko, A., Petas, A. & Taari, K. Tranexamic acid in control of primary hemorrhage during transurethral prostatectomy. Urology 64, 955-958 (2004). (Pubitemid 39469513)
73. Miller, R. A., May, M. W., Hendry, W. F., Whitfield, H. N. & Wickham, J. E. The prevention of secondary haemorrhage after prostatectomy: the value of antifibrinolytic therapy. Br. J. Urol. 52, 26-28 (1980). (Pubitemid 10152828)
74. Ruel, M. A. et al. Is tranexamic acid safe in patients undergoing coronary endarterectomy? Ann. Thorac. Surg. 71, 1508-1511 (2001).
75. Fergusson, D. A. et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N. Engl. J. Med. 358, 2319-2331 (2008). (Pubitemid 351749156)
76. Schelin, S. Transurethral resection of the prostate after intraprostatic injections of mepivacain epinephrine: a preliminary communication. Scand. J. Urol. Nephrol. 43, 63-67 (2009).
77. Herr, H. W. The enlarged prostate: a brief history of its surgical treatment. BJU Int. 98, 947-952 (2006). (Pubitemid 44536437)
78. Mercier, L. Recherches sur le traitement des maladies des organs urinaires. (Kessinger publishing, Paris, 1856).
79. Bottini, E. La galvanocaustica nella practica chirurgica. (Novara, 1873).
80. Beer, E. Landmark article May 28, 1910. Removal of neoplasms of the urinary bladder. By Edwin Beer. JAMA 250, 1324-1325 (1983).
81. Stern, M. Resection of obstruction at the vesicle orifice; new instruments resectotherm; resectoscope and new method. JAMA 87, 1726-1730 (1926).
82. Gupta, N., Sivaramakrishna, Kumar, R., Dogra, P. N. & Seth, A. Comparison of standard transurethral resection, transurethral vapour resection and holmium laser enucleation of the prostate for managing benign prostatic hyperplasia of 40 g. BJU Int. 97, 85-89 (2006).
83. Fowler, C., McAllister, W., Plail, R., Karim, O. & Yang, Q. Randomised evaluation of alternative electrosurgical modalities to treat bladder outflow obstruction in men with benign prostatic hyperplasia. Health Technol. Assess. 9, iii-iv, 1-30 (2005).
84. Lourenco, T. et al. Minimally invasive treatments for benign prostatic enlargement: systematic review of randomised controlled trials. BMJ 337, 966-973 (2008).
85. Bhansali, M., Patankar, S., Dobhada, S. & Khaladkar, S. Management of large (60 g) prostate gland: PlasmaKinetic Superpulse (bipolar) versus conventional (monopolar) transurethral resection of the prostate. J. Endourol. 23, 141-145 (2009).
86. Tan, A. H. & Gilling, P. J. Holmium laser prostatectomy: current techniques. Urology 60, 152-156 (2002). (Pubitemid 34722968)
87. Vavassori, I., Hurle, R., Vismara, A., Manzetti, A. & Valenti, S. Holmium laser enucleation of the prostate combined with mechanical morcellation: two years of experience with 196 patients. J. Endourol. 18, 109-112 (2004). (Pubitemid 38295674)
88. Hoffman, R. M., MacDonald, R., Slaton, J. W. & Wilt, T. J. Laser prostatectomy versus transurethral resection for treating benign prostatic obstruction: a systematic review. J. Urol. 169, 210-215 (2003). (Pubitemid 35461590)
89. Pedraza, R., Samadi, A. & Eshghi, M. Holmium laser enucleation of the prostate in critically ill patients with technique modification. J. Endourol. 18, 795-798 (2004). (Pubitemid 39441775)
90. Lee, J. & Gianduzzo, T. R. Advances in laser technology in urology. Urol. Clin. North Am. 36, 189-198 (2009).
91. Gilling, P. J., Aho, T. F., Frampton, C. M., King, C. J. & Fraundorfer, M. R. Holmium laser enucleation of the prostate: results at 6 years. Eur. Urol. 53, 744-749 (2008). (Pubitemid 351273870)
92. Elzayat, E. A., Al-Mandil, M. S., Khalaf, I. & Elhilali, M. M. Holmium laser ablation of the prostate versus photoselective vaporization of prostate 60 cc or less: short-term results of a prospective randomized trial. J. Urol. 182, 133-138 (2009).
93. Okamura, K. et al. Perioperative management of transurethral surgery for benign prostatic hyperplasia: A nationwide survey in Japan. Int. J. Urol. 18, 304-310 (2011).
94. Ruszat, R. et al. Safety and effectiveness of photoselective vaporization of the prostate (PVP) in patients on ongoing oral anticoagulation. Eur. Urol. 51, 1031-1038 (2007).
95. Ruszat, R. et al. Comparison of potassium-titanyl-phosphate laser vaporization of the prostate and transurethral resection of the prostate: update of a prospective non-randomized two-centre study. BJU Int. 102, 1432-1438 (2008).
96. Bouchier-Hayes, D. M., Anderson, P., Van Appledorn, S., Bugeja, P. & Costello, A. J. KTP laser versus transurethral resection: early results of a randomized trial. J. Endourol. 20, 580-585 (2006). (Pubitemid 44689646)
97. Ruszat, R. et al. GreenLight laser vaporization of the prostate: single-center experience and long-term results after 500 procedures. Eur. Urol. 54, 893-901 (2008).
98. Wendt-Nordahl, G. et al. Systematic evaluation of a recently introduced 2-microm continuous-wave thulium laser for vaporesection of the prostate. J. Endourol. 22, 1041-1045 (2008). (Pubitemid 351693950)
99. Xia S. J. et al. Thulium laser versus standard transurethral resection of the prostate: a randomized prospective trial. Eur. Urol. 53, 382-389 (2008).
100. Bach, T. et al. Thulium: YAG 2 mum cw laser prostatectomy: where do we stand? World J. Urol. 28, 163-168 (2010).